Compare IDEXX Laboratories, Inc. (IDXX) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Marsh & McLennan Companies, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Marsh & McLennan Companies, Inc. trades at $175.94 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 2.1× IDEXX Laboratories, Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| IDXX | MRSH | |
|---|---|---|
Market Cap | $40.43B | $84.31B |
Volume | 692,164 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $766.68 | $207.02 |
52-Week Low | $504.70 | $157.32 |
Typical Hold Time | 46 Days | 109 Days |
Enterprise Value | $41.32B | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Marsh (MRSH) trades at $175.76, up 1.21% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust fundamentals, including a 25.72% ROE and 14.24% net income margin, alongside the recent acquisition of Accel Holdings announced on October 2, 2026. Revenue has grown steadily, reaching $27.0B in 2025, though profit margins have slightly softened.
The outlook remains positive with a consensus price target of $202.71, implying 15% upside, but risks include high valuation multiples and competitive pressures. Analysts are predominantly neutral, with 65% hold ratings, suggesting cautious optimism amid solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
